[New methods of thrombolysis].

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Context:

• Classical thrombolytic therapy using streptokinase presents challenges due to antigenicity and significant effects on the clotting system.
• Emerging thrombolytic agents, including urokinase, plasmin, and tissue plasminogen activator (t-PA), are physiological substances with reduced antigenicity.
• Understanding the distinct mechanisms and systemic effects of these agents is crucial for optimizing clinical thrombolysis.

Purpose:

• To review and compare different clinical thrombolysis strategies.
• To evaluate the advantages and disadvantages of novel thrombolytic agents compared to traditional therapies.
• To present clinical outcomes associated with newer thrombolytic drugs.

Summary:

• Streptokinase therapy, while effective, is limited by antigenicity and substantial influence on coagulation.
• Urokinase and plasmin, though non-antigenic, exhibit varying degrees of impact on the clotting system, with urokinase requiring potential heparin co-administration.
• Tissue plasminogen activator (t-PA) demonstrates enhanced fibrin-specific binding and resistance to inhibitors upon adsorption to fibrin, leading to targeted clot lysis with minimal systemic coagulation alteration.

Impact:

• The findings support the clinical utility of t-PA for effective and safer thrombolysis.
• This review aids clinicians in selecting appropriate thrombolytic agents based on patient-specific factors and desired outcomes.
• The study highlights advancements in thrombolytic therapy, paving the way for improved treatment of thrombotic conditions.